Leptin as a key driver for organ fibrogenesis

Area of Science:

• Biochemistry
• Immunology
• Pathology

Background:

• Leptin, a hormone from adipocytes, regulates metabolism and energy balance.
• Leptin signaling is increasingly linked to the development of tissue fibrosis.
• The leptin receptor (LEPR) mediates leptin's biological effects.

Purpose of the Study:

• To elucidate the structural basis of leptin-neutralizing antibody (hLep3) interaction with leptin.
• To evaluate the therapeutic efficacy of hLep3 in preclinical models of fibrosis.
• To explore the mechanistic role of leptin signaling in fibrosis pathogenesis.

Main Methods:

• X-ray crystallography was used to determine the structures of hLep3 unbound and bound to leptin.
• Therapeutic potential was assessed using multiple mouse models of organ fibrosis (kidney, liver, lung, heart, blood vessels).
• Mechanistic investigations focused on inflammatory and profibrotic pathways.

Main Results:

• The antibody's binding mode to leptin mimics that of the leptin receptor, revealing its neutralization mechanism.
• Leptin neutralization via hLep3 treatment markedly inhibited fibrosis progression in all tested mouse models.
• Suppression of leptin activity was shown to reduce pro-inflammatory and profibrotic signaling.

Conclusions:

• Leptin signaling is a critical driver of fibrosis across diverse tissues.
• A leptin-neutralizing antibody (hLep3) demonstrates significant therapeutic potential for treating fibrotic diseases.
• Targeting leptin offers a promising strategy for anti-fibrotic therapies.